Resmed Inc
NYSE:RMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Resmed Inc
Cash from Financing Activities
Resmed Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Resmed Inc
NYSE:RMD
|
Cash from Financing Activities
-$796.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
-$395m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Financing Activities
-$956.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-8%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
$113m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$6.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
-$2.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
N/A
|
|
Resmed Inc
Glance View
ResMed Inc. has built its legacy on a profound, technological commitment to improving the lives of millions worldwide who suffer from sleep-related breathing disorders. Emerging as a beacon in the field of medical device innovation, the company is renowned for its focus on designing and manufacturing equipment to treat sleep apnea, a condition where breathing repeatedly stops and starts during sleep. Their product line, which includes continuous positive airway pressure (CPAP) devices, ventilators, and masks, caters to hospitals, home healthcare settings, and individuals. By addressing this critical health issue, ResMed doesn't just deliver therapeutic equipment; it offers a lifeline to those battling sleep health challenges, ensuring that restful nights translate into healthier days. The company's revenue model pivots around an integrated approach combining hardware sales, software solutions, and cloud-connected offerings. Through its software, ResMed analyzes vast pools of patient data, enabling healthcare providers to tailor and improve therapeutic protocols, thus driving the efficacy of treatment plans. The increasing turn towards digital health technologies has also opened new avenues, with the company's cloud platforms and analytics delivering value-added insights to care providers. This convergence of medical equipment and digital technology provides ResMed not just a steady growth trajectory, but also positions it at the forefront of a healthcare evolution, turning data-driven intelligence into actionable health solutions.
See Also
What is Resmed Inc's Cash from Financing Activities?
Cash from Financing Activities
-796.6m
USD
Based on the financial report for Dec 31, 2025, Resmed Inc's Cash from Financing Activities amounts to -796.6m USD.
What is Resmed Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-9%
Over the last year, the Cash from Financing Activities growth was 22%.